Eko Health Raises $41 Million to Scale AI-Driven Heart & Lung Disease Detection

Eko Health Raises $41 Million to Scale AI-Driven Heart & Lung Disease Detection

Client News

Related Solutions

Providing a strategic, multidisciplinary approach to help clients develop and use AI and to navigate the landscape of Big Data.
Helping clients launch their businesses and transform their innovative ideas into successful companies.
Comprehensive counseling for healthcare providers, insurers and the companies that supply them with products and services.

On June 5, 2024, Eko Health, a pioneer in applying artificial intelligence for early detection of heart and lung diseases, announced it has raised $41 million in Series D financing. With participation by ARTIS Ventures, Highland Capital Partners, NTTVC and Questa Capital, the funding round will be used to expand US and global access to the company’s early disease detection platform.

The WilmerHale team advising Eko Health consisted of Joe Wyatt, Shafi Armatis and Sharon Baek.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel